People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

People using GLP-1 medications are more likely to suffer severe acid reflux, a new study suggests. Researchers found patients ...

A similar study in Gastro Hep Advances found higher odds of GERD and gastroparesis among patients with type 2 diabetes taking GLP-1 agonists versus SGLT-2 inhibitors, but lower odds of acute ...

Patients with COPD and type 2 diabetes had a reduced risk for COPD hospitalization, noninvasive positive-pressure ventilation and all-cause mortality if they used an SGLT-2 inhibitor, according to ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

SGLT-2 inhibitor vs DPP-4 inhibitor use was associated with a further reduced incidence of epilepsy among female patients (HR, 0.54; 95% CI, 0.32-0.90) than male patients ...

Data continue to indicate that use of SGLT-2 inhibitors in clinical practice is associated with a lower risk for cardiovascular events across the board, now in a more diverse population, a finding ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ.

A recent review in Current Diabetes Reports delves into the utility of sodium-glucose co-transporter-2 (SGLT2) inhibitors for patients with heart failure currently on other medications.

A recent study discovered that individuals using GLP-1 medications may develop severe acid reflux.Researchers discovered that ...